BEAM

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company founded in 2017 and based in Cambridge, Massachusetts. The company went public in February 2020 and has emerged as a leader in precision genetic medicine, specifically focusing on base editing technology to develop treatments for serious genetic diseases. Beam has built a comprehensive pipeline of experimental therapies targeting blood disorders, liver diseases, and other genetic conditions, with several programs advancing through clinical trials.